A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

BACKGROUND: Inhibition of the programmed cell death protein 1 (PD‐1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kinase (BTK) inhibition may suppress myeloid‐de...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tian, Harrison, Michael R., O'Donnell, Peter H., Alva, Ajjai S., Hahn, Noah M., Appleman, Leonard J., Cetnar, Jeremy, Burke, John M., Fleming, Mark T., Milowsky, Matthew I., Mortazavi, Amir, Shore, Neal, Sonpavde, Guru P., Schmidt, Emmett V., Bitman, Bojena, Munugalavadla, Veerendra, Izumi, Raquel, Patel, Priti, Staats, Janet, Chan, Cliburn, Weinhold, Kent J., George, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590121/
https://www.ncbi.nlm.nih.gov/pubmed/32757302
http://dx.doi.org/10.1002/cncr.33067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590121/
https://www.ncbi.nlm.nih.gov/pubmed/32757302
http://dx.doi.org/10.1002/cncr.33067

Ejemplares similares